Nizatidine 300 MG Oral Capsule

INDICATIONS AND USAGE Nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.

Actavis Pharma, Inc.

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] fatigue` `[3] off label use` `[4] nausea` `[5] dyspnoea` `[6] diarrhoea` `[7] pain` `[8] headache` `[9] seizure` `[10] dizziness`

4 years ago

CAPSULE BROWN 3138 WPI

HOW SUPPLIED

NIZATIDINE capsules, USP are available as follows: 150 mg - Size #2, two-piece hard-gelatin buff opaque capsules imprinted “ 3137 ” on cap and “ WPI ” on body. capsules are supplied in bottles of 60 (NDC 0591-3137-60). 300 mg - Size #0, two-piece hard-gelatin light brown opaque capsules imprinted with “ 3138 ” on cap and “ WPI ” on body. capsules are supplied in bottles of 30 (NDC 0591-3138-30). Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP. Manufactured In India By: Watson Pharma Private Limited Verna, Salcette Goa 403 722 INDIA Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054 Rev. A 6/2022

More pills like CAPSULE 3138 WPI

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site

Nizatidine 300 MG Oral Capsule

FDA Reported Adverse Reactions [1] drug ineffective [2] fatigue [3] off label use [4] nausea [5] dyspnoea [6] diarrhoea [7] pain [8] headache [9] seizure [10] dizziness

CAPSULE BROWN 3138 WPI

More pills like CAPSULE 3138 WPI

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] fatigue` `[3] off label use` `[4] nausea` `[5] dyspnoea` `[6] diarrhoea` `[7] pain` `[8] headache` `[9] seizure` `[10] dizziness`